投资机构奥本海默近日发布研报,首次将康乃德生物医药纳入研究覆盖范围,并给予其“跑赢大盘”的积极评级。该机构为这家生物技术公司设定的目标股价为每股8美元。
投资机构奥本海默近日发布研报,首次将康乃德生物医药纳入研究覆盖范围,并给予其“跑赢大盘”的积极评级。该机构为这家生物技术公司设定的目标股价为每股8美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.